What is Pharma Two B?
Pharma Two B operates as a specialized entity within the biotechnology sector, focusing on the development of advanced therapeutic solutions. The company distinguishes itself through a rigorous research-driven methodology, aiming to address unmet medical needs through high-impact pharmaceutical innovation. By maintaining a lean operational structure and fostering strategic partnerships, Pharma Two B has established a robust framework for clinical development and long-term value creation. Its market position is bolstered by a clear focus on therapeutic efficacy and the integration of sophisticated scientific methodologies, positioning the firm as a key player in the evolving life sciences ecosystem.
How much funding has Pharma Two B raised?
Pharma Two B has raised a total of $38M across 2 funding rounds:
Series B
$8M
Private Equity
$30M
Series B (2012): $8M with participation from JK&B Capital
Private Equity (2017): $30M led by Generali Group, JK&B Capital, Israel Biotech Fund, and JVC
Key Investors in Pharma Two B
JK&B Capital
A Chicago-based venture capital firm managing over $1.1 billion, specializing in the Communications, Information Technologies, and Healthcare sectors with a focus on trend-enabling technologies.
Generali Group
A global insurance and financial services provider that leverages deep local knowledge and international expertise to deliver innovative life, general, and specialty insurance solutions.
Israel Biotech Fund
An investment firm based in Rehovot, Israel, dedicated to supporting the growth and development of companies within the biotechnology and life sciences industries.
What's next for Pharma Two B?
With the recent capital injection, Pharma Two B is well-positioned to accelerate its clinical trial programs and expand its research infrastructure. The strategic focus will likely shift toward optimizing the commercialization pathway for its lead candidates, while simultaneously exploring new therapeutic indications. As the company transitions into this next phase of development, the emphasis will remain on maintaining operational excellence and leveraging the expertise of its institutional partners to navigate complex regulatory environments. Future growth will be predicated on the successful execution of its R&D roadmap and the continued validation of its proprietary technology, ensuring sustained momentum in the global healthcare market.
See full Pharma Two B company page
